Incident non-infectious uveitis risk after immune checkpoint inhibitor treatment.

Our findings suggest that, while incident uveitis is rare in patients with cancer treated with anti-PD-1/PD-L1 inhibitors, there is an increased risk in those with skin melanoma, warranting vigilant monitoring for uveitis in this subgroup.